Option chain shows key data for Tevogen Bio Holdings's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Tevogen Bio Holdings.

Tevogen Bio Holdings (NASDAQ:TVGN) Stock, Option Chain

Tevogen Bio Holdings

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes ("CD8+ CTLs" or "CTLs"), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.

Nvidia, Palantir, Clover Health, Joby Aviation, Tesla: Why These 5 Stocks Are On Investors' Radars Today

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

DBGI

DXYZ

HCWB

HOTH

JXJT

KEYS

KITT

KORE

POWL

PRFX

QDEL

RIME

SOAR

TNXP

TVGN

WKHS

XTKG

Why Keysight Technologies Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket

stock chart-1863880_1920-60

Tevogen Bio Holdings Inc. (NASDAQ: TVGN) shares are trading higher Monday, potentially driven by momentum from a late-Friday announcement regarding operational updates. Here&#39;s what you need to know.

Tevogen Bio Shares Are On The Rise Monday: What&#39;s Going On?

Exclusives

AAPL

AMZN

DRUG

GLMD

GNPX

INTC

LUNR

MSFT

MSTR

NVDA

OKLO

PLTR

SMCI

SOFI

TSLA

WHLR

WULF

A look at the most-searched tickers on Benzinga Pro for the month of October. Donald Trump and biotech stocks joined the top 10.

EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank?

Tevogen Bio Holdings Inc

Altus Power, the largest commercial-scale provider of clean electric power, today announced the acquisition of a 3.4 MW solar project from Chaberton Energy, a Maryland-based national renewable energy project developer, which Altus Power will complete development of and then construct. Upon completion, the power generated by the asset, owned and operated by Altus and located in East New Market, Maryland, will deliver the benefits of clean, electric power to the local community, through Maryland's Community Solar Energy Generating Systems (CSEGS) pilot program.

AMPS

Altus Power Announces Acquisition Of 3.4 MW Community Solar Development Project In Maryland From Chaberton Energy; No Financial Terms Disclosed

Deere &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) reported a fourth-quarter net sales and revenue decline of 28% year-over-year to $11.143 billion, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42107405/deere-reports-net-income-of-1-245-billion-for-fourth-quarter-7-1-billion-for-fiscal-year" rel="noreferrer noopener">beating the consensus of $9.335 billion.</a>
Deere clocked an EPS of $4.55, down from $8.26 YoY, beating the consensus of $3.90.
Production &amp; Precision Agriculture net sales declined 38% YoY to $4.305 billion, Small Agriculture &amp; Turf net sales fell 25% to $2.306 billion, and Construction &amp; Forestry revenue declined 29% to $2.664 billion due to lower shipment volumes.
Financial services revenues grew 13% year over year to $1.522 billion. Net income declined to $173 million from $190 million a year ago due to higher credit loss provisions, partially offset by portfolio income, lower SA&amp;G expenses, and valuation gains.
Operating profit fell 52.1% YoY to $1.45 billion, and margin contracted by 661 bps to 13%. Segment operating margins: Production &amp; Precision Agriculture 15.3%, down YoY from 26.4%; Small Agriculture &amp; Turf 10.1%, down YoY from 14.4%; Construction &amp; Forestry 12.3%, down YoY from 13.8%.
As of October 27, Deere held $8.5 billion in cash and equivalents. DE&#8217;s net cash provided by operating activities for the fiscal was $9.231 billion, compared to $8.589 billion a year ago.
In the third&nbsp;quarter, the company launched employee-separation programs across the U.S., Europe, Asia, and Latin America to align with strategic priorities and reduce redundancies. These largely involuntary programs incurred $157 million pretax ($124 million after-tax) in 2024, with $130 million paid.
&#8220;Amid significant market challenges this year, we proactively adjusted our business operations to better align with the current environment. Together with the structural improvements made over the past several years, these adjustments enable us to serve our customers more effectively and achieve strong results across the business cycle,&#8221; commented John May, chairman and CEO of Deere.
Guidance: Deere projects fiscal 2025 net income to be between <a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">$5.0 billion and $5.5 billion.</a> For fiscal-year 2024, net income attributable to Deere was $7.100 billion. 
The company said it remains committed to making investments that enhance customer productivity and profitability.
Price Action: DE shares traded higher by 1.49% at $411.00 premarket at the last check Thursday.
Photo via Shutterstock

Earnings

Equities

Guidance

Deere Q4 Earnings: Beats Expectations, Steep Sales Drop, Margins Squeeze & More

WIIM

Yunji shares are trading lower after the company reported a year-over-year decrease in Q3 financial results.

Wells Fargo analyst Roger Read maintains EOG Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EOG#NYSE">EOG</a>) with a Equal-Weight and raises the price target from $135 to $147.

Price Target

Analyst Ratings

Wells Fargo Maintains Equal-Weight on EOG Resources, Raises Price Target to $147

Article Focuses on how Leading Physicians are Incorporating Nociscan Into Their Clinical Practices for Chronic Low Back Pain Patients
MAGNETOM Flash is a Peer-to-Peer Magazine Published by Siemens to Showcase Advancing Technologies in the MRI Space
The RSNA Edition Coincides With the Annual Meeting of the Radiology Society of North America (RSNA)
BROOMFIELD, Colo., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:<a href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today its Nociscan product is featured in the RSNA Edition of Siemens Healthineers magazine, MAGNETOM Flash. The RSNA annual meeting is December 1-4, 2024. The inclusion of Nociscan highlights the challenges of chronic low back pain and illustrates the growing importance of MR spectroscopy (MRS) as an innovative decision support tool for physicians.

Biotech

General

ACON

Aclarion Announces Its Nociscan Product Is Featured In The RSNA Edition Of Siemens Healthineers Magazine, MAGNETOM Flash; Article Focuses On How Leading Physicians Are Incorporating Nociscan Into Their Clinical Practices For Chronic Low Back Pain Patients

Susquehanna analyst Shyam Patil maintains Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) with a Positive and maintains $150 price target.

Susquehanna Maintains Positive on Trade Desk, Maintains $150 Price Target

CATO

Cato shares are trading lower after the company reported a year-over-year decrease in Q3 financial results.

LMND

Lemonade shares are trading higher after Piper Sandler maintained a Neutral rating on the stock and raised its price target from $25 to $44.

Wells Fargo analyst Sarah Akers maintains Spire (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SR#NYSE">SR</a>) with a Equal-Weight and raises the price target from $73 to $75.

Wells Fargo Maintains Equal-Weight on Spire, Raises Price Target to $75

Susquehanna analyst Christopher Rolland maintains STMicroelectronics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>) with a Positive and maintains $33 price target.

Susquehanna Maintains Positive on STMicroelectronics, Maintains $33 Price Target

Osisko Development shares are trading higher after the company announced it secured key permits for its Cariboo Gold project in British Columbia.

SOLOWIN HOLDINGS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIN#NASDAQ">SWIN</a>) ("SOLOWIN" or the "Company"), a leading financial services firm providing high-net-worth and institutional investors with solutions across traditional and virtual assets, today announced its strategic partnership with Zodia Custody, a leading institution-first digital asset custodian backed by Standard Chartered, which has been selected by NASDAQ as a new core custodian for its suite of crypto indexes, to strengthen Hong Kong's digital asset ecosystem. This partnership aims to offer secure, bank-grade and compliant custody services in Hong Kong for SOLOWIN's clients.
Zodia Custody will be one of several custody providers available to Solowin's diverse client base, enhancing the range of options offered with its additional layers of security, control and bank-grade compliance for their digital asset holdings. In addition, SOLOWIN and Zodia Custody will jointly explore opportunities to combine their expansive resources and global regulatory licensing framework (existing and future) to maximize synergies and capitalize on growing investor demand in the region. All offerings will be subject to necessary regulatory approvals.

Global

SWIN

SOLOWIN Signs Strategic Partnership With Zodia Custody To Facilitate Hong Kong's Digital Asset Ecosystem; Partnership Aims To Offer Secure, Bank-Grade And Compliant Custody Services In Hong Kong For SOLOWIN's Clients

Susquehanna analyst Christopher Rolland maintains Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) with a Positive and raises the price target from $55 to $60.

SMTC

Susquehanna Maintains Positive on Semtech, Raises Price Target to $60

BMRA

Biomerica Secures Three European Patents For inFoods Technology Targeting GERD, Crohn's Disease, And Ulcerative Colitis, Positioning To Address $8.4B+ Market Across 30+ Nations Within The European Patent Treaty

– In two studies the acellular tissue engineered vessel (ATEV) provided benefits in terms of patency, limb salvage, and infection resistance compared to current synthetic graft treatment benchmarks –
– Results were published in a premier peer-reviewed surgical journal sponsored by the American Medical Association –
DURHAM, N.C., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced the publication of clinical results evaluating the efficacy and safety of the acellular tissue engineered vessel (ATEV) in the repair of extremity civilian and military injuries in JAMA Surgery, an American Medical Association peer-reviewed journal. The publication "Bioengineered Human Arteries for the Repair of Vascular Injuries" describes two clinical studies in which the ATEV demonstrated benefits in terms of patency (blood flow), limb salvage, and infection resistance compared to synthetic graft benchmarks in the treatment of acute vascular injuries of the extremities.

HUMA

Humacyte Announces The Publication Of Clinical Results Evaluating The Efficacy And Safety Of The Acellular Tissue Engineered Vessel In The Repair Of Extremity Civilian And Military Injuries In Jama Surgery, An American Medical Association Peer-Reviewed Journal

CRKN

Crown Electrokinetics shares are trading higher. The company provided comments about the potential impact of the Trump Administration and the EPA on its lead pipe detection and remediation businesses.

Susquehanna analyst Shyam Patil maintains Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Positive and raises the price target from $420 to $435.

PANW

Susquehanna Maintains Positive on Palo Alto Networks, Raises Price Target to $435

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

TuanChe Enters Advisory Agreement With Waterside Inc. To Assist  TuanChe In 'identifying suitable cryptocurrency mining equipment and related resources'

Contracts

NVEE

NV5 Announces $14M In Municipal Infrastructure Contracts In Southern California

TRNR

Interactive Strength shares are trading higher after the company announced its board approved a Bitcoin purchase plan worth up to $5 million.

Tevogen Bio, Rani Therapeutics, and Expion360 are the 3 Penny Stocks to watch on October 15, 2024, based on&nbsp;TipRanks' Penny Stock Screener too...

3 Penny Stocks to Watch Now, 10/15/24

Tevogen (TVGN) Bio reported last week that Chief Scientific Officer Dr. Neal Flomenberg sold shares. "Tevogen's Chief Financial Officer, Kirti Desa...

Tevogen says CSO share sale 'solely' to satisfy payment of tax obligations

Tevogen Bio (TVGN) announces its Artificial Intelligence effort, Tevogen AI, has joined Microsoft (MSFT) for Startups. This partnership marks a sig...

Tevogen AI joins Microsoft for Startups

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: McDonald's (MCD) shares are continuing...

McDonald's down after outbreak, Starbucks slides after warning: Morning Buzz

Tevogen (TVGN) Bio provided additional guidance on the first clinical product of the company's proprietary ExacTcell technology, TVGN 489, designed...

Tevogen provides more guidance on ExacTcell technology

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Boeing (BA) will offer 90M shares of c...

Boeing to offer 90M common shares, Philips reports mixed Q3: Morning Buzz

Tevogen (TVGN) announced that it received written notice from the Listing Qualifications Staff of Nasdaq stating that the company has regained comp...

Tevogen regains compliance with Nasdaq

Tevogen Bio (TVGN) announced its Artificial Intelligence effort, Tevogen.AI, had partnered with Microsoft (MSFT) (MSFR) Using Microsoft's suite of ...

Tevogen leverages Microsoft partnership to deliver target identification for HPV

Tevogen Bio Holdings reports Q3 results

Kirti Desai, CPA, Tevogen's (TVGN) CFO, commented, "The company is in a unique position as it relates to reporting intangible assets on our balance...

Tevogen reports Q3 EPS (3c) vs (3c) last year

ARLP

COIN

CORZ

CPAY

CSTM

EBAY

ENPH

EQNR

GLUE

GOOG

GOOGL

NPPXF

NTTYY

PRCT

RANI

REAL

SAVE

SBUX

SNAP

ULCC

XPON

Financing

Press Releases

Alpha Capital Appointed as Exclusive Financial Advisor to CD8 Technology to Secure Funding Up To $50 Million

Tevogen Bio Reports Nasdaq Listing Compliance as CEO Reaffirms His Commitment in Bridging the Information Gap About the Company

Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing Costs

Tevogen Bio Announces Appointment of Anthony Tarantino as Patient Advocate to Enhance Community Engagement and Patient Support

Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920

Management

Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Company's Novel Business Model as Key to Sustainable Success through Patient Affordability

Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations

Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials

UPDATE - Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials

Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model

Comments

Tevogen Bio Holdings

Tevogen Bio Holdings (TVGN) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga